The effect of paricalcitol on osteoprotegerin production by human peripheral blood mononuclear cells

Journal of Rheumatology

Volumn 36, Issue 4, 2009, Pages 856-

  Eleftheriadis, Theodoros ^a,b   Antoniadi, Georgia ^c   Liakopoulos, Vassilios ^d   Galaktidou, Grammati ^a  

^a THEAGENIO CANCER HOSPITAL   (Greece)

^b General District Hospital of Serres   (Greece)

^c General Hospital of Serres   (Greece)

^d UNIVERSITY HOSPITAL OF LARISSA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; INTERLEUKIN 8; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARICALCITOL; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D; ERGOCALCIFEROL;

ADULT; ANTIINFLAMMATORY ACTIVITY; BONE EROSION; CELL CULTURE; CYTOKINE PRODUCTION; DRUG SAFETY; FEMALE; HUMAN; HYPERCALCEMIA; IMMUNOMODULATION; INFLAMMATORY DISEASE; INFORMED CONSENT; LETTER; MALE; NORMAL HUMAN; OSTEOBLAST; OSTEOCLAST; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SECONDARY HYPERPARATHYROIDISM; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL;

ADULT; ERGOCALCIFEROLS; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; OSTEOPROTEGERIN;

EID: 66149133275     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080987     Document Type: Letter

References (11)

1. Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 2007;9 Suppl:S1-S7.
2. Li Y, Toraldo G, Li A, et al. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 2007;109:3839-48.
3. Nakashima T, Takayanagi H. The dynamic interplay between osteoclasts and the immune system. Arch Biochem Biophys 2008;473:166-71.
4. Kondo T, Kitazawa R, Maeda S, Kitazawa S. 1 alpha,25 dihydroxyvitamin D3 rapidly regulates the mouse osteoprotegerin gene through dual pathways. J Bone Miner Res 2004;19:1411-9.
5. Nakashima T, Kobayashi Y, Yamasaki S, et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 2000;275:768-75.
6. van Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 2005;97:93-101.
7. Cutolo M, Otsa K, Laas K, et al. Circannual vitamin D serum levels and disease activity in rheumatoid arthritis: Northern versus Southern Europe. Clin Exp Rheumatol 2006;24:702-4.
8. Cutolo M, Otsa K, Uprus M, Paolino S, Seriolo B. Vitamin D in rheumatoid arthritis. Autoimmun Rev 2007;7:59-64.
9. Eleftheriadis T, Liakopoulos V, Antoniadi G, Stefanidis I, Galaktidou G. Paricalcitol at clinically achievable concentration decreases basal and LPS induced TNF-a and IL-8 production by human peripheral blood mononuclear cell [abstract]. Abstract book, 7th Annual Conference on Prevention in Renal Disease, Toronto, Canada, September 19-20, 2008: 8.
10. Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriol resistant secondary hyperparathyroidism. Am J Kidney Dis 38;5 Suppl:S45-50.
11. Lindberg J, Martin KJ, Gonzalez EA, Acchiardo SR, Valdin JR, Soltanek C. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol 2001;56:315-23.